The present podcast gives a short summary of the PAOLA-1 trial investigating the addition of Olaparib to bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer tr
The infiltration of tumor-infiltrating B cells and plasma cells in early-stage breast cancer has been associated with a reduced risk of distant metastasis. However, the…
Read it now on PracticeUpdate.com
Read it now on PracticeUpdate.com
The older population represents ∼50%-60% of the population of newly diagnosed patients with cancer. Due to physiological and pathological aging and the increased presence of…
The management of hormone receptor-positive (HR+) early breast cancers (EBC) is based on a risk-adapted optimization strategy escalating adjuvant endocrine treatment (ET) with the addition…
In the era of precision oncology, the management of triple-negative breast cancer (TNBC) is rapidly changing and becoming more complicated with a variety of chemotherapy,…
The increasing use and anticipated future adoption of antibody–drug conjugates (ADCs) present a significant challenge in identifying and monitoring patients for the development of potentially…
Targeting HER2-low gastric cancer, summary by Erman Akkus / A Ooki, Ankara University Faculty of Medicine, Breast Cancer, cancer, Erman Akkus, ESMO Open,
Therapeutic developments in the targeting of human epidermal growth factor receptor 2 (HER2)-expressing gastric cancer have followed the dramatic success of HER2-expressing breast cancer treatment,…
Interstitial lung disease (ILD) encompasses a heterogeneous group of disorders sharing pathophysiological inflammatory mechanisms, leading to parenchymal distortions. The prevalence of ILD with new cancer…
